2seventy/BMS’s Abecma Shines In Earlier Lines, But J&J/Legend’s Carvykti May Have Edge

Without disclosing data, 2seventy and BMS reported positive Phase III results in third-line and beyond multiple myeloma, but Carvykti will soon have second-line data.

Executives at 2seventy Bio, Inc. were tight-lipped during their second-quarter earnings call about detailed results from the Phase III KarMMa-3 clinical trial of chimeric antigen receptor T-cell (CAR-T) therapy Abecma (idecabtagene vicleucel) in third- to fifth-line multiple myeloma, but the data seem to leave the CAR-T therapy well-positioned to significantly expand its pool of eligible patients. However, the product’s chief competitor – Johnson & Johnson and Legend Biotech Corp.’s Carvykti (ciltacabtagene autoleucel) – may end up extending its reach into an even earlier-line treatment first.

Bristol Myers Squibb Company and 2seventy announced positive top-line results on 10 August from KarMMa-3, the same day that 2seventy announced its second quarter earnings. However, the partners did...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

More from Anticancer